Board of Directors

Dr Mo Dirani is currently the CEO of Plano Pte Ltd. Mo completed his PhD at the age of 26 years, where he established the world’s largest twin study to investigate the genetic and environmental risk factors of myopia. In 2008, Mo undertook a post-doctoral appointment at the National University of Singapore (NUS), where he co-led a study that produced one of the first and most cited scientific papers on the protective nature of outdoor activity in the development of myopia.

Mo has published over 100 peer-reviewed manuscripts in prestigious medical journals, regularly invited to speak as an expert in myopia across the globe, published several Government commissioned reports and has received several competitive scholarships, fellowships and scientific awards.

More recently (2015-2017), Mo led Australia’s first nation-wide study to assess the burden of blindness in Indigenous and non-Indigenous Australians, completed his MBA at the Australian Institute of Business (AIB) and is a graduate from the Australian Institute of Company Directors (AICD).


Professor Darren Kelly is currently the CEO of OccuRx and Certa Therapeutics, bringing over 25 years of management and research expertise in the life sciences and biotech sector. Concurrent to these roles, Darren is the Associate Dean (Innovation and Enterprise) at The University of Melbourne, the Director of Innovation and Enterprise at the Centre for Eye Research Australia (CERA) and the Director Biomedical Research in the Department of Medicine, St Vincent’s Hospital Melbourne, where his research expertise lies in progressing pre-clinical novel interventions and developing experimental models of cardiovascular disease.

He has published over 200 manuscripts in the field of translational research and novel interventions many of which have had a direct impact on human disease. In 2015 Darren joined the Medical Research Commercialisation Fund as Venture Partner. Darren has a PhD in Translational Medicine from the University of Melbourne, and an Executive Diploma Business Administration. He is a current member of the Australian Institute of Company Directors, AusBiotech, BioMelbourne Network and a Fellow of the American Society of Nephrology.


Professor Jonathan Crowston is a clinician-scientist and Visiting Professor of Ophthalmology at Duke/NUS Singapore. Until recently he served as Director of the Centre for Eye Research Australia. He completed his ophthalmology training at Moorfields Eye Hospital in London, a PhD at UCL and postdoctoral work at UC San Diego.

His research aims to understand why aging renders the optic nerve vulnerable to glaucoma and to develop optic nerve targeted treatments enhancing neurorecovery as well as clinical tools for assessing these. He has published 170 pubmed listed manuscripts, is founder of Oculo (, serves as a clinical and scientific advisor to a number of biotech companies and has received a number of awards for his research.


Chief Executive Officer

Dr. Arif Jubaer is a serial entrepreneur and founder of Daily Positive (D+)-a media agency of positive news, Arif Systems-an IT & business consultancy firm and Babatye- an online clothing brand. In last 15 years, based on his unique experiences both in academic and industry world, Arif has setup business strategies, processes, policies and led product development for large enterprises and mid-to-small size businesses.

Arif completed his PhD at the University of Melbourne in Information and Communication Technology in 2010. Since then Arif has been working as sessional lecturer at various reputed universities in Australia..


Chief Operating Officer

Dr Lauren Giorgio is currently the Business Development Manager at the Centre for Eye Research Australia. Concurrent to this role, she is Market Analyst at OccuRx, Program Director for the Women in Leadership Development Program, and Chair of the Australian Science and Innovation Forum.

Previously, Lauren has held positions at the Walter and Eliza Hall Institute and Flinders Partners, and has completed an internship with Brandon Capital Partners under the Medical Research Commercialisation Fund program. Lauren has a first-class Honours degree in Health Science and a PhD in cancer biology from the University of Adelaide. She is also graduate of the Australian Institute of Company Directors.

All copy rights reserved by EtAl

Designed by Smitiv